Orilissa Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7462625 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jan, 2021

(3 years ago)

US6872728 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jan, 2021

(3 years ago)

US7056927 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(a month from now)

US7419983 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2029

(4 years from now)

US11542239 ABBVIE Elagolix sodium compositions and processes
Jul, 2039

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7179815 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Mar, 2021

(3 years ago)

US7176211 ABBVIE Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(8 days ago)

US11707464 ABBVIE Methods of treating heavy menstrual bleeding
Mar, 2034

(9 years from now)

US11344551 ABBVIE Methods of treating heavy menstrual bleeding
Mar, 2034

(9 years from now)

US10682351 ABBVIE Methods of administering elagolix
Sep, 2036

(12 years from now)

US10537572 ABBVIE Methods of administering elagolix
Sep, 2036

(12 years from now)

US11690854 ABBVIE Methods of treating heavy menstrual bleeding
Apr, 2038

(13 years from now)

US11690845 ABBVIE Methods of administering elagolix
Aug, 2040

(16 years from now)



Orilissa is a drug owned by Abbvie Inc. It is used for managing moderate to severe pain associated with endometriosis. Orilissa uses Elagolix Sodium as an active ingredient. Orilissa was launched by Abbvie in 2018. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 27, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 23, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 23 July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix for up to 24 months; Use of elagolix 200 ...

Dosage: TABLET

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents